Condition
Cardiovascular Disease
Locations
Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark,
Germany, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands,
Poland, Puerto Rico, Serbia, South Africa, Spain, Thailand, Turkey,
United Kingdom, United States
Start date
01/03/2023
Summary
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Mar 01 2023 - Oct 13 2027
Estimated enrollment
7000
Phase
Not Available
Are you eligible?
Gender
Male and female
Age
55 years and older
Other
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.